GLP-1 drugs work while you take them. Surgery works while you follow it. The right answer depends on which commitment fits your life.
GLP-1 receptor agonists produce meaningful weight loss without surgery and improve glycaemic control. For patients below the surgical threshold, or unwilling to have an operation, they are a genuine option — and we say so.
Weight is typically regained after stopping, side effects lead many to discontinue, cost accumulates indefinitely, and long-term data beyond a few years is still emerging. Surgery has decades of follow-up.
GLP-1 therapy achieves roughly 15–20% total body weight loss in trials; sleeve and bypass typically achieve 25–35% and sustain it for longer. For someone with a BMI of 45, that difference is decisive.
Increasingly, drugs are used before surgery to reduce liver size and operative risk, or afterwards to manage regain. Treating them as rivals is outdated — the question is sequencing, not either/or.
Yes, and it is a recognised strategy for insufficient loss or regain, under supervision.